Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Partnership with the American Oncology Network
Hematologic Oncology Update
00:00
Third‑line options after BTK and venetoclax
She recommends clinical trials, pirtobrutinib, CAR‑T or allogeneic transplant discussions for younger patients with double‑refractory CLL.
Play episode from 36:59
Transcript
